Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid

Eligibility Criteria

• * Body mass index between 18.0 and 32.0 kilograms per meter squared (kg/m2), inclusive, and a body weight of ≥50 kg.
• * In good health, as determined by no clinically significant findings from medical history, 12-lead electrocardiogram (ECG) and vital signs measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia \[e.g., suspicion of Gilbert's syndrome based on total and direct bilirubin\] is not acceptable) at screening and check-in, and from the physical examination at check-in, as assessed by the Investigator (or designee).
• * Have a 12-lead ECG abnormality that, in the opinion of the Investigator,
• * increases the risk associated with participating in the study
• * may confound ECG data analysis
• * a QTcF: \>450 millisecond (msec) for males, or \>470 msec for females
• * short PR interval \<120 msec or PR interval \>220 msec
• * second or third degree atrioventricular block
• * intraventricular conduction delay with QRS \>120 msec
• * complete right bundle branch block
• * left bundle branch block, or
• * Wolff Parkinson-White syndrome
• * Have a current or recent acute, active infection (for example, for a least 30 days before screening and up to Day -1, participants must have no symptoms or signs of infection in the absence of any anti-infective treatment).
• * Had any malignancy within the past 5 years. Exceptions: successfully treated basal cell skin carcinoma or squamous cell skin carcinoma, with no evidence of recurrence or metastatic disease within the 3 years prior to baseline.
• * Have inflammatory bowel disease (IBD), including ulcerative colitis or Crohn's disease.